JPRN-UMIN000033182
Completed
Phase 2
A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H) - TMB-H basket
ational Cancer Center Hospital East0 sites70 target enrollmentStarted: August 10, 2018Last updated:
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- ational Cancer Center Hospital East
- Enrollment
- 70
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.History of highly sensitive reactions to other antibody formulations. 2\.Considered that side effects from previous medication or surgery affect the safety assessment. 3\.Complication or a history of chronic or recurrent autoimmune disease. 4\. History of another malignancy within 3 years of baseline (BL). 5\. Have central nervous system metastasis. 6\. Complications or history of interstitial lung disease, pulmonary fibrosis or radiation pneumonitis. 7\. Complication of Diverticulitis or symptomatic gastrointestinal ulcer disease. 8\. Have pericardial effusion, pleural effusion or ascites requiring sustained treatment. 9\. Uncontrolled tumor associated pain. 10\. History of transient cerebral ischemic attack or cerebral vascular accident within 180 days of BL. 11\. History of thrombosis or thromboembolism. 12\. cardiovascular disease. 13\. Uncontrollable diabetes mellitus. 14\. Have systemic infection requiring treatment. 15\. Requires or has a history of transplantation therapy. 16\. History of severe allergy. 17\. Have bowel obstruction. 18\. Received following therapies within 28 days of BL \- systemic adrenocortical hormone or immunosuppressant. \- other unapproved drugs \- adhesions such as pleura or pericardium \- surgical therapy with general anesthesia \- radiation therapy 19\. Received following therapies within 14 days of BL \- any antineoplastic agent \- surgical therapy with local or surface anesthesia 20\. Received radiopharmaceuticals within 56 days of BL. 21\. Either HIV antibody, HBs antigen or HCV antibody test is positive. 22\. Pregnant, nursing or suspected pregnancy. 23\. Previous therapeutic history for anti\-PD\-1, anti\-PD\-L1, anti\-PD\-L2, anti\-CD 137, anti\-CTLA\-4 antibody or other T cell regulation. 24\. Patient lacking consent ability
Investigators
Similar Trials
Completed
Phase 2
A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Studypleural mesothelioma10027412NL-OMON41970Antoni van Leeuwenhoek Ziekenhuis33
Active, not recruiting
Not Applicable
ivolumab in patients with progressive malignant pleural mesothelioma: NivoMesA single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes StudyMedDRA version: 17.1Level: LLTClassification code 10027408Term: Mesothelioma malignant advancedSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003935-20-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Active, not recruiting
Phase 1
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid TumorsEUCTR2013-002844-10-FIBristol-Myers Squibb International Corporation1,620
Active, not recruiting
Phase 1
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid TumorsAdvanced or metastatic solid tumors:1) Triple Negative Breast Cancer (TNBC)2) Gastric Cancer (GC)3) Pancreatic Cancer (PC)4) Small Cell Lung Cancer (SCLC).5) Bladder Cancer (BC)6) Ovarian Cancer (OC)MedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-002844-10-DEBristol-Myers Squibb International Corporation1,620
Active, not recruiting
Phase 1
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid TumorsAdvanced or metastatic solid tumors:1) Triple Negative Breast Cancer (TNBC)2) Gastric Cancer (GC)3) Pancreatic Cancer (PC)4) Small Cell Lung Cancer (SCLC).MedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-002844-10-ITBristol-Myers Squibb International Corporation200